O	0	7	Mitotic
O	8	13	index
O	14	17	and
O	18	25	benefit
O	26	28	of
B-intervention	29	37	adjuvant
I-intervention	38	51	anthracycline
I-intervention	51	52	-
I-intervention	52	57	based
I-intervention	58	70	chemotherapy
O	71	73	in
O	74	82	patients
O	83	87	with
O	88	93	early
O	94	100	breast
O	101	107	cancer
O	107	108	.

O	109	111	We
O	112	116	have
O	117	126	evaluated
O	127	134	whether
O	135	138	the
O	139	146	mitotic
O	147	152	index
O	153	158	could
O	159	166	predict
O	167	170	the
O	171	178	benefit
O	179	181	of
O	182	190	adjuvant
O	191	204	anthracycline
O	204	205	-
O	205	210	based
O	211	223	chemotherapy
O	224	226	in
B-eligibility	227	235	patients
I-eligibility	236	240	with
I-eligibility	241	246	early
I-eligibility	247	253	breast
I-eligibility	254	260	cancer
I-eligibility	261	264	who
I-eligibility	265	268	are
I-eligibility	269	277	eligible
I-eligibility	278	281	for
I-eligibility	282	290	adjuvant
I-eligibility	291	303	chemotherapy
I-eligibility	304	313	according
I-eligibility	314	316	to
I-eligibility	317	322	Saint
I-eligibility	323	329	Gallen
I-eligibility	330	340	guidelines
O	340	341	.

O	342	343	A
O	344	349	total
O	350	352	of
B-total-participants	353	356	937
O	357	365	patients
O	366	370	from
O	371	372	a
O	373	379	single
O	380	391	institution
O	392	396	were
O	397	405	included
O	406	408	in
O	409	412	two
O	413	423	randomized
O	424	430	trials
O	431	435	that
O	436	444	compared
O	445	453	adjuvant
O	454	467	anthracycline
O	467	468	-
O	468	473	based
O	474	486	chemotherapy
O	487	491	with
B-control	492	494	no
I-control	495	507	chemotherapy
O	507	508	.

O	509	514	These
O	515	523	patients
O	524	531	account
O	532	535	for
O	536	538	83
O	538	539	%
O	540	542	of
O	543	546	the
O	547	554	overall
O	555	565	population
O	566	574	included
O	575	577	in
O	578	583	these
O	584	590	trials
O	590	591	.

O	592	595	The
O	596	601	first
O	602	607	trial
O	608	616	included
O	617	630	premenopausal
O	631	639	patients
O	640	644	with
O	645	649	node
O	649	650	-
O	650	658	negative
O	659	666	disease
O	666	667	,
O	668	671	and
O	672	675	the
O	676	682	second
O	683	686	one
O	687	695	included
O	696	710	postmenopausal
O	711	719	patients
O	719	720	,
O	721	731	regardless
O	732	734	of
O	735	740	lymph
O	741	745	node
O	746	752	status
O	752	753	.

O	754	757	The
O	758	767	treatment
O	768	775	benefit
O	776	779	was
O	780	788	assessed
O	789	798	according
O	799	801	to
O	802	805	the
O	806	812	number
O	813	815	of
O	816	823	mitoses
O	824	827	per
O	828	833	field
O	834	835	(
O	835	839	x400
O	839	840	)
O	840	841	.

O	842	845	The
O	846	853	mitotic
O	854	859	index
O	860	863	was
O	864	874	assessable
O	875	877	in
B-total-participants	878	881	888
O	882	890	patients
O	891	892	(
O	892	894	94
O	894	895	%
O	895	896	)
O	896	897	.

O	898	901	All
O	902	905	the
O	906	914	patients
O	915	924	presented
O	925	927	as
O	928	934	either
O	935	939	node
O	939	940	-
O	940	948	positive
O	949	951	or
O	952	954	an
O	955	962	average
O	962	963	-
O	963	967	risk
O	968	974	breast
O	975	981	cancer
O	982	991	according
O	992	994	to
O	995	999	2003
O	1000	1005	Saint
O	1006	1012	Gallen
O	1013	1022	consensus
O	1023	1033	conference
O	1034	1044	guidelines
O	1044	1045	.

O	1046	1049	The
B-outcome	1050	1051	5
I-outcome	1051	1052	-
I-outcome	1052	1056	year
I-outcome	1057	1064	overall
I-outcome	1065	1073	survival
I-outcome	1074	1079	rates
O	1080	1084	were
B-iv-bin-percent	1085	1087	91
I-iv-bin-percent	1087	1088	%
O	1089	1092	and
B-cv-bin-percent	1093	1095	87
I-cv-bin-percent	1095	1096	%
O	1097	1100	for
O	1101	1109	patients
O	1110	1117	treated
O	1118	1120	or
O	1121	1124	not
O	1125	1129	with
O	1130	1138	adjuvant
O	1139	1151	chemotherapy
O	1152	1153	(
O	1153	1154	P
O	1155	1156	=
O	1157	1158	.
O	1158	1160	09
O	1160	1161	)
O	1161	1162	.

O	1163	1165	In
O	1166	1174	patients
O	1175	1179	with
O	1180	1183	low
O	1183	1184	/
O	1184	1190	medium
O	1191	1198	mitotic
O	1199	1204	index
O	1205	1206	(
O	1206	1207	<
O	1208	1213	three
O	1214	1221	mitoses
O	1221	1222	/
O	1222	1227	field
O	1227	1228	;
O	1229	1230	n
O	1231	1232	=
O	1233	1236	450
O	1236	1237	)
O	1237	1238	,
O	1239	1242	the
B-outcome	1243	1244	5
I-outcome	1244	1245	-
I-outcome	1245	1249	year
I-outcome	1250	1257	overall
I-outcome	1258	1266	survival
I-outcome	1267	1271	rate
O	1272	1275	was
B-iv-bin-percent	1276	1278	95
I-iv-bin-percent	1278	1279	%
O	1280	1283	for
O	1284	1292	patients
O	1293	1300	treated
O	1301	1303	or
O	1304	1307	not
O	1308	1312	with
O	1313	1321	adjuvant
O	1322	1334	chemotherapy
O	1335	1336	(
O	1336	1337	P
O	1338	1339	=
O	1340	1341	.
O	1341	1343	56
O	1343	1344	)
O	1344	1345	.

O	1346	1348	In
O	1349	1357	patients
O	1358	1362	with
O	1363	1367	high
O	1368	1375	mitotic
O	1376	1381	index
O	1382	1383	(
O	1383	1384	>
O	1384	1385	/
O	1385	1386	=
O	1387	1392	three
O	1393	1400	mitoses
O	1400	1401	/
O	1401	1406	field
O	1406	1407	;
O	1408	1409	n
O	1410	1411	=
O	1412	1415	438
O	1415	1416	)
O	1416	1417	,
O	1418	1421	the
B-outcome	1422	1423	5
I-outcome	1423	1424	-
I-outcome	1424	1428	year
I-outcome	1429	1436	overall
I-outcome	1437	1445	survival
I-outcome	1446	1451	rates
O	1452	1456	were
B-iv-bin-percent	1457	1459	86
I-iv-bin-percent	1459	1460	%
O	1461	1464	and
B-cv-bin-percent	1465	1467	79
I-cv-bin-percent	1467	1468	%
O	1469	1472	for
O	1473	1481	patients
O	1482	1489	treated
O	1490	1492	or
O	1493	1496	not
O	1497	1504	treated
O	1505	1509	with
O	1510	1518	adjuvant
O	1519	1531	chemotherapy
O	1531	1532	,
O	1533	1545	respectively
O	1546	1547	(
O	1547	1548	P
O	1549	1550	=
O	1551	1552	.
O	1552	1554	02
O	1554	1555	)
O	1555	1556	.

O	1557	1558	A
O	1559	1563	high
O	1564	1571	mitotic
O	1572	1577	index
O	1578	1580	is
O	1581	1591	associated
O	1592	1596	with
O	1597	1600	the
O	1601	1609	efficacy
O	1610	1612	of
O	1613	1621	adjuvant
O	1622	1635	anthracycline
O	1635	1636	-
O	1636	1641	based
O	1642	1654	chemotherapy
O	1655	1657	in
O	1658	1666	patients
O	1667	1675	eligible
O	1676	1679	for
O	1680	1688	adjuvant
O	1689	1701	chemotherapy
O	1702	1704	in
O	1705	1710	daily
O	1711	1719	practice
O	1719	1720	.
